Isomorphic Labs Raises $5 Billion in Series C Funding
Isomorphic Labs, Alphabet's AI-driven drug discovery unit led by Nobel laureate Demis Hassabis, has closed a $5 billion Series C round co-led by Greenoaks and Sequoia Capital, with a16z joining as a new investor and Alphabet continuing to commit heavily. The proceeds will fund foundational simulation models, expand internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.
Related Entities
Full Report
IT之家 November 17 news: Isomorphic Labs, an AI-powered drug discovery company under Alphabet led by Nobel laureate Demis Hassabis, announced today local time that it has completed a $5 billion (IT之家 note: approximately 33.396 billion RMB at current exchange rates) Series C funding round.

This funding round was co-led by Greenoaks and Sequoia Capital, with new investors including a16z (Andreessen Horowitz) joining, Alphabet continuing to invest substantial funds, and existing investors such as Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund also participating in the financing.
Isomorphic Labs plans to use this funding to continue advancing the development of foundational simulation models, expanding the scale of internal and partnered drug candidate programs, and building global AI-driven bioengineering infrastructure.